This research examines how biomarkers (genes, proteins, brain activity) can predict treatment outcomes in patients with clinical depression.
Participants with depression will receive standard antidepressant medication for 12 weeks, meet regularly with a study doctor, complete cognitive tasks and surveys about their mood, complete study visits every 2 weeks for 12 weeks and receive honorarium for study participation.
Eligibility Criteria
- Age Range: 18-65 years old
- Currently feeling depressed (Group 1) OR no history of psychiatric illness (Group 2)
- No history of bipolar disorder
What does the study involve?
- Number of contacts: 7-9 sessions
- Format of Study: Hybrid (mix of in-person and virtual visits)
- Compensation offered: Yes
Investigator(s): Dr. Stefan Kloiber
Full Study Title: Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
Contact Information:
E-mail: optimumd@camh.ca
REB number: 119/2021
REB Approval Expiry Date: November 27, 2026
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.